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A

growing number of clinical trials incorporate
invasive procedures like nondiagnostic tumor
biopsies for biomarker or pharmacodynamic
analysis.1 Such invasive research procedures are ethically contentious. Tumor biopsies involve pain and
complication risk,2 and at least one procedure-related
death has been reported.3 However, nondiagnostic tumor biopsies obtained in the research context generally
have no value for managing the participant’s medical
condition. Some commentators therefore argue that
research biopsies “take” from participants without
“giving in return.”4
Because such procedures are conducted contrary
to research participants’ medical interests, an ethical
framework for enrolling patients in studies that include
a research biopsy rides heavily on informed consent. In
particular, study participants should understand that
research biopsies are nontherapeutic and burdensome
and that participation is discretionary in studies involving them. Yet little is known about whether decisions
to enroll in a study that involves a research biopsy,
including those that permit participants to opt out of
the procedure, meet thresholds of consent validity, in
other words, whether individuals sufficiently understand and appreciate the consequences of their decision
and whether they are not unduly influenced.5 Some
studies about research biopsies suggest that individuals
often misconstrue nondiagnostic biopsies as therapeutic;6 others suggest the contrary.7 Interpreting these
findings is further complicated by the fact that because
participants were often enrolled in clinical drug trials,
they might have legitimately imputed therapeutic value
to research biopsies when receiving access to investigaAbadie R, Kimmelman J, Lafleur J, Lemmens T. Consent for nondiagnostic
research biopsies: A pilot study of participant recall and therapeutic orientation. IRB: Ethics & Human Research 2014;36(3):9-15.

tional drugs was conditioned on providing a biopsy for
research.8
There are at least three reasons that clinical trials
that include research biopsies might present challenges
for consent validity. First, because procedures are burdensome, individuals who enroll in these trials might
do so under the mistaken belief that the biopsies provide a therapeutic benefit to them. Second, biopsies are
often conducted proximate to therapeutic encounters,
where patients undergoing a biopsy might be focused
on a recent diagnosis and on management options,
not on their role as a research participant. Last, some
argue that because research participants often conflate
research with clinical care,9 they might fail to appreciate the nontherapeutic nature of a research biopsy. To
investigate these issues, we used semistructured interviews to probe recalled perceptions, motivations, and
consent quality for research participants in a cancer
biomarker study involving nondiagnostic biopsies.

Study Methods

O

ur primary goal was to describe the extent to
which research participants with confirmed breast
cancer diagnoses ascribed therapeutic orientation to
nondiagnostic tumor biopsies in biomarker studies
(hereinafter “parent studies”) in which they had previously participated. Our study was conducted at a major
cancer research and treatment hospital in metropolitan
Montreal.
Prospective participants for the biomarker studies
arrived at the research site—a breast cancer clinic—on
referral after a positive mammogram. In the first appointment, these patients were informed of the need
for a diagnostic biopsy and approached about enrolling in three studies involving nondiagnostic breast
tumor biopsies. Consent for research biopsies was
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Table 1.
Demographics of Patient-Respondents
Individual

Age (yrs)		

Race/Ethnicity		

Highest Educational Level		

Date of First Diagnosis

N01 		34		White			Bachelor’s degree			January 2011
N02		84		White/Italian		Fifth grade			1990
N03		60		White			Bachelor’s degree			September 2010
N04		
47		
White/Middle Eastern
Bachelor’s degree 		
March 2011
					
N05		43		White			High school graduate		2010 			
			
N06		62		Asian/Pakistani		High school graduate		January 2011
					
N07		47		White/Mohawk		High school graduate		December 2010
					
N08		42		White/Middle Eastern
Master’s degree			November 2011
N09		67		White/Portuguese

Fifth grade			1998

N10		48		White/Ashkenazi 		Bachelor’s degree 		2009

sought during the patients’ initial visits by the head
nurse (responsible for intake of patients at the clinic,
discussing diagnostic biopsies, and overseeing research),
and research biopsies were obtained by a radiologist
(not the principal investigator or care surgeon) in the
same session during which clinically indicated biopsies
were collected (except in one case, where a participant
received diagnostic and research biopsies on a return
visit). Research biopsies required additional needle
trajectories; three were sought from each patient, and a
research nurse was present during the procedures. Biopsies were performed either during the first meeting or a
few days later. All women received standard of care for
their cancer, and none were participating in drug trials.
The benefits section of the consent documents stated,
“There will be no direct benefit to you by taking part
in this research . . . . While not directly offering you a
specific therapeutic benefit, the careful follow-up may
well represent a degree of improved quality of care for
you.” As a condition of granting us access to participants in the parent studies, the biomarker research
team required that we interview women after the last
follow-up session for the parent studies.
n Semistructured Interviews. The theory guiding
our interview template is described elsewhere.10 Briefly,
M ay -J u n e 2014
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we designed a 30-minute interview template probing
three domains: motivation for enrollment, comprehension, and voluntariness. Participants in the parent
studies were approached to participate in our interview
study after their last research follow-up—typically six
months after undergoing the research biopsies. We
also conducted 20-minute interviews with the principal investigator (a surgeon-oncologist) of the parent
studies and the head nurse to assess their perception of
informed consent quality; interviews were recorded and
transcribed.
Interviews were conducted in English by Roberto
Abadie, between December 2011 and April 2012,
recorded, and transcribed. Coding was performed
independently by Roberto Abadie and Jonathan Kimmelman, using an iterative process. Interviews were
interpreted using grounded theory.11 This facilitated
development of analytically meaningful coding schemes
and attachment of codes to text segments. We measured the frequency with which codes appeared. Codings were compared until a consensus was reached on
categories and definitions. Following Miles and Huberman,12 we targeted inter-rater agreement of 80%.
Analysis ended once all transcripts had been coded and
saturation obtained (a list of codes is available from the
IRB: E t h i c s & H u m a n R e s e a rc h

authors). The study was approved by the institutional
review board (IRB) at the hospital hosting the parent
study, and all participants provided written informed
consent.

Study Results

A

ll of the individuals approached (10 in total)
agreed to participate in our interview study.
We were unable to interview patients declining research biopsies, primarily because refusal was rare.
Table 1 shows the demographics of participants we
interviewed. Most of the participants were Caucasian, though the sample was diverse in terms of age,
socioeconomic status, and length of time since initial
diagnosis. Two patients entered the parent study after
relapse (patients N02 and N09). The mean time between biopsy and interview was 14.18 months (range:
2-30 months).
n Motivation for Enrolling in Biopsy Study. We
began the interview by asking why each woman had
agreed to undergo research biopsies. Without exception, respondents offered reasons rooted in altruism,
for instance: “If we can help another patient in the future, by all means, let’s help” (N02). And as described
below, some responses were tinged with expressions of
reciprocity toward previous study subjects or the study
team.
Respondents often appealed to their identification
with other members of society in explaining their motivations. One respondent said, for example,
I am like you, and you are like me, and I am like my
family, like my neighbor, your mother, your sister. We
are all people on this planet, and I feel like they all are
like me. And if they can benefit from what I do in the
future, then it is good. My daughter, maybe 20, 30
years from now might be diagnosed. (N07)

Consistent with previous studies of nontherapeutic
research,13 responses often evoked benefits flowing to
family members. In no instance did respondents describe primary motivators as therapeutic or diagnostic
access or collateral benefits like extra contact with the
study team.
n Comprehension of Benefits and Purpose. When
asked about direct benefits of participation, all respondents accurately stated that there were none: “[I]mmediate expectations from this would be nil,” one stated.
I never expected that” (N02). We probed with slightly
different wording for confirmation. In every case,
respondents accurately stated that there were no direct
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benefits from the research biopsies. The investigators of
the parent study correctly predicted this nontherapeutic orientation. Nevertheless, we occasionally heard a
response that attributed indirect benefits to participation, including the prospect that discoveries might be
relevant to participants, as well as increased monitoring. For instance, once respondent noted that “anytime
that I had a question, if I felt funny, or if it was something new because I am very vigilant of anything that
happens to me, I call my nurse, I call Dr. X’s secretary,
and if needed, I can be at the hospital if not the same
day, the day after” (N01).
Most respondents were also able to accurately state
that they had participated in a research study. However,
two harbored misunderstandings. In one case, a respondent (the one who described “helping other women”
as her primary motivation for enrollment) believed that
the biomarker study involved a “phase IV” drug trial

Because nondiagnostic research biopsies are
conducted contrary to research participants’
medical interests, an ethical framework for
enrolling patients in studies that include a research
biopsy rides heavily on informed consent.
(N10). Another respondent seemed unable to recall she
had undergone a research biopsy: “I don’t think we really were asked to do anything extra. I don’t think they
told us, we are doing this because of the research only.”
(N02)
Despite emphatically altruistic motivations for enrolling in the parent studies, respondents were disengaged from the substance of the research. The consent
form stated,
The purpose of this study is to understand why tumors
become resistant to anticancer treatment. To understand clinical resistance, we need to obtain small pieces
of tumor (biopsies) from your primary breast lesions .
. . we hope to understand resistance to the particular
anticancer treatment that you are receiving . . . we want
to find markers that are associated with resistance to
the anticancer treatment. Markers are proteins found in
tumor tissue . . . that are resistant to treatment.

However, none of the respondents could state the
study’s purpose. One respondent’s answer was, “I don’t
know. I was under the impression that they were taking
samples and then researchers would do research using
my tissue” (N07). And another respondent said, “Why
M ay -J u n e 2014
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is he doing this? I guess it is because he has a research
clinic and he wants further improvement for breast
cancer in women” (N03). The medical team accurately
surmised that participants in their study would be disengaged with the research objectives. As one principal
investigator predicted, “They wouldn’t know that we
are sequencing the tumor . . . but they might know that
we are doing research to understand how the tumors
work.”
Few of the respondents reported contemplating future impacts of research findings, though according to
one respondent, “You hope [advances] are possible, but
I don’t think about that” (N05). Most were unable to
estimate the probability that the studies would produce
a major medical advance. One respondent said, “I’ll say
50/50; I don’t have a clue, no clue” (N04), and another
said, “I have no knowledge of research” (N06). When
pressed, many respondents offered expectations exceeding historic odds of medical breakthroughs. When
asked whether long odds of a breakthrough might have
deterred their enrollment, one respondent’s resolve to
participate seemed to intensify: “We need even more
because if you have a smaller rate of success, you need
more people and everything to make progress” (N05).
n Recall and Perception of Risk. Breast tumor
biopsies are associated with discomfort and complication risk. We probed the extent to which respondents
understood risk and drew on this knowledge in their
decision-making about enrolling in the biopsy study.
Even after having participated in the parent study,
many participants were unable to recall any risks, and
some reported being indifferent to burdens at the time
of deciding whether to enroll. According to one respondent, “[The biopsy] didn’t seem like a big deal because
it didn’t take very long and it is not that invasive”
(N01). The following dialogue captures the spirit of
many responses:
Interviewer: [W]hen you do the biopsy for diagnosis,
you have two tissue samples, and then if you do the
research biopsy, you undergo three more additional
extractions.
N06: [Smiles.] [O]ne time, two times, three times, four
times. It doesn’t matter!
Interviewer: You were not worried about the pain or
the bleeding?
N06: No. I wanted to help other people, and also some
pain and bleeding are to be expected.

When asked to recall the biopsy, most respondents
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described burdens as modest to minor. Said one respondent, “I had a little bit of bruising after the biopsy, but
it was not a concern. It didn’t scare me, and it didn’t
concern me” (N05). Yet when asked to rate the pain
on a scale from 1 to 10 (with 10 being the highest), respondents generally scored pain at 5 or 6. Some noted
that, in contrast with those associated with chemotherapy, biopsy burdens were transient and did not threaten
physical identity, by, for instance, rendering a patient
publicly ill the way hair loss can. However, two respondents considered burdens significant and described
them as equal to or greater than chemotherapy. One
respondent applied a score of 9 to the biopsy, describing it as “very painful” (N06). Another respondent emphasized experiential aspects of the procedure: “[I]t is
very invasive. The needle is big, but that doesn’t bother
me. What bothers me, it’s the click; it is like a point
that comes and grabs the tissue . . . . I remember myself
thinking, I wish it’s a good one, I don’t want them to
take more, make it a good one” (N07). No respondents
reported being surprised about the level of burden.
n Voluntariness. Along with capacity and comprehension, freedom from undue influence is an essential
element of valid consent.14 We asked a series of questions about perceptible factors that might have adversely affected voluntary decision-making.
Respondents did not report any pressure to enroll
in the parent study and reportedly perceived ample
opportunity to query investigators and to decline to
participate. When asked whether declining might have
adversely affected their medical care, respondents
generally replied in the negative: “I don’t think that Dr.
X would treat me any different if I agree to participate
or not to participate” (N08). Yet, two participants suggested that this was a possibility: “That’s a good question,” one replied (N01), and another said, “I think
being part of the study, the treatment . . . I was better
treated, I think . . . better supported . . . better followed . . . . Maybe they were more ‘there’ because they
needed certain things or they needed to know more or
how I felt or what I did” (N04).
n Decision-Making Process. To better understand
why many respondents seemed unperturbed by research burdens, we asked a series of questions about
the decision-making process. Many respondents said
enrolling in the parent study was an easy decision to
make. One replied, for example, “To be honest, didn’t
give it a lot of thought” (N02). Another said, “I wanted
to sign it the same day, but the oncology nurse was
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not there anymore so I think that it was a week after”
(N10). Three respondents recalled asking questions
about the research, and enrolling in the parent study
gave one respondent pause. “[I]initially,” she explained,
“we didn’t know how much tissue he was going to
remove and . . . we were a little bit concerned that
because of this study he was going to remove some
nodes no matter what, but then he told us that he was
going to remove them anyway. So I didn’t see any harm
in participating” (N01). Most respondents recalled that
the research decision-making context was distracting
and overwhelming. In some cases, this led to indifference. As one respondent said,
We have so many things in our minds, [research] is
the least of our concerns [laughs] . . . . [I] think that
[subjects] are probably not well informed but not
because the information isn’t there. It is just that the
concerns they are dealing with, whether they are going
to go through or not, that’s their main concern. I mean,
clearly, that’s the priority for them. (N02)

Yet some respondents said they were overwhelmed,
with one explaining,
[I]t is so much information, getting all the documents,
absorbing all the information is hard. . . . I couldn’t
process all the information; even after, I would ask,
What did he say? We are relatively educated people and
can ask questions, so I can imagine how other people
that might be older or with fewer resources, or another
language might have more difficulty understanding.
(N01)

Another respondent described the consent process as
follows: “They tell you okay, we are going to do this
and this and this. You are not mentally there; you are
in shock” (N05).
n Additional Themes. Our interviews uncovered
several additional themes. First, though some respondents expressed skepticism about medicine or research,
all showed unswerving confidence in both the institution and study team. As one stated, “I don’t expect
the research performed at [institution] to be harmful” (N01). Respondents also deferred all aspects of
moral decision-making or science to the institution or
researchers. For instance, some said they were comfortable knowing little if anything about the research. “I
don’t need to know everything,” one respondent said.
“I don’t want him to waste time, so I said, Where do I
sign? As I said before, I really trust them” (N05). And
another said, “I am sure that there are people [at the
hospital] that struggle with [the risk or benefit]” (N01).
Even in this unusual research setting where research
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procedures occurred outside of a trial where drugs
were being administered, another theme emerged from
accounts of research intertwined with those of care. In
particular, beliefs and convictions arising out of care
shaped the research encounter. The following quotation, prompted by a question about concerns on entering the parent study, illustrates the way trust, built in
the care setting, grounded confidence in the research: “I
put my trust in [the physician-investigator] and in God.
First God [laughs]. The first time I met [the physicianinvestigator]—he is such a sweet person. I was scared;
I was discouraged; I asked [him], ‘Do you believe in
God?’ He said, ‘Yes.’ I said, ‘Me too, let’s work at this
together!’” (N03)
Finally, the theme of reciprocity also emerged. Some
respondents regarded participation as an act of care
for the investigators: “It’s me almost saying, ‘What

Interview responses from our study paint a
reassuring picture about informed consent for
research biopsies—respondents recruited from a
parent study did not demonstrate a propensity to
view an invasive nondiagnostic biopsy as
therapeutic.
can I do to help you?’” one said (N05), and another
explained, “Sometimes I would ask Dr. X, ‘So, was I a
good patient for you, a good subject?’” (N02)

Discussion

T

he interview responses from our study paint a reassuring picture about informed consent for research
biopsies, at least for the parent studies from which our
respondents were recruited. Respondents did not demonstrate a propensity to view an invasive nondiagnostic
biopsy as therapeutic. This was in spite of a somewhat suggestive phrase in the consent form describing
potential benefits due to “careful follow-up.” Instead,
they consistently recalled altruism as their primary if
not exclusive motivation to enroll in the parent study,
understood they had participated in research, and perceived the research biopsies correctly as nontherapeutic.
They further recalled comprehending risk and expressed no surprise at the level of burden experienced.
None of the respondents perceived pressure to enroll in
the parent study, and several cited the consent process
as evidence of voluntary decision-making. These find-
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ings are inconsistent with some studies suggesting that
research participants occasionally view research biopsies as therapeutic.15 These differences may reflect our
particular research site. They may also reflect the fact
that respondents in our study were not participating in
drug trials involving experimental treatments. Given
the fluidity with which respondents transitioned from
discussing treatment to research, differences may also
reflect our sustained and careful probing of therapeutic
perceptions.
Notwithstanding altruistic motivation for enrolling
in the parent study, the answers respondents gave to
our questions suggest they were preoccupied with their
diagnosis and treatment during the consent process for
the parent study. Most recalled being disengaged in the
research itself, as indicated by rapid decision-making,
scarce questioning, poor recollection of objectives,
and little contemplation of research benefits. Instead,
decision-making about the parent study was embedded
within a network of trust relations toward the investigators, institutions, and the research enterprise.16 That
is, respondents generally entrusted moral and scientific
matters relating to how the study was carried out to
the research team and research systems. Disclosure
elements during the consent process did not appear
to play a direct role in decision-making, though the
enactment of consent seemed to engender perceptions
of researcher and institutional trustworthiness. These
findings underline the point that informed consent is no
substitute for independent risk and benefit review. They
also make clear that informed consent and IRB review
of protocols—in addition to serving substantive ethical
ends—help sustain relationships that make burdensome
research possible.17
Findings from our pilot study also leave many
unanswered questions. To what extent are responses at
this research site representative of other sites? Would
perceptions about therapeutic orientation differ if the
parent study had been an investigational drug trial?
Where does the trust that underlies altruistic motivations originate, how is it sustained, and how resilient
is it? And above all, are perceptions reported here a
reliable proxy for perceptions of research participants
during the informed consent process itself?
Our findings are subject to several limitations. First,
our sample was small and limited to one site. Though
interviews converged on key themes, our findings
should be replicated before drawing conclusions about
consent validity for studies that include a research
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biopsy. Second, interviews were conducted months, and
in some cases years, after the biopsies were conducted,
as we were unable to obtain permission from study investigators to interview patients during or immediately
after the consent process for the parent studies. Recall
of a consent process and of the information conveyed
is an imperfect representation of the actual process and
decision-making at that time, and respondents likely
came to understand the research they were in and their
relationship with the study team better after having
participated in it. Third, the biopsy study team’s knowledge that we were studying their consent process may
have induced more scrupulous conduct. We consider
this unlikely, however, as biopsies had been collected
from most of our respondents before we initiated our
research. Fourth, our research was partially funded
by the team that conducted the biopsies. Maintaining
critical distance from funders and parent-study investigators is always a methodological challenge; we leave it
to others to decide whether we effectively navigated this
relationship.
Disclosure
The authors declare no commercial interest in the
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